Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020
11 June 2021
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
BioEscalator Pitch Battle 2021
9 June 2021
PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.
MoA Technology Graduates from The BioEscalator
1 June 2021
MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
HRH The Earl of Wessex visits Oxfordshire virtually
18 May 2021
HRH The Earl of Wessex speaks with Oxfordshire entrepreneurs, including Atherton Mutombwera, CEO of Hutano Diagnostics.
MoA Technology secures further funding
27 April 2021
MoA Technology, a spin-out company from Oxford University’s Department of Plant Sciences, has secured an additional £5M funding for its series A round to support the expansion and acceleration of its discovery programme.
Alchemab raises £60M Series A funding
16 April 2021
The biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
Virginia Corless joins MoA Technology as CEO
12 March 2021
MoA Technology has a new CEO, Dr Virginia Corless, an experienced leader of cutting-edge enterprises that aim to make agriculture more efficient and sustainable.
MediMabBio raises $18M Series A funding
26 February 2021
BioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.
PepGen Announces Formation of Scientific Advisory Board
26 February 2021
PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the peptide-mediated delivery of nucleic acid therapeutics, has announced the formation of its Scientific Advisory Board.
PepGen appoints James McArthur as President and CEO
4 February 2021
BioEscalator resident biotech PepGen, has announced the appointment of serial entrepreneur Dr James McArthur as President and Chief Executive Officer (CEO). The McGill alumnus brings a wealth of experience in guiding early and clinical-stage healthcare ventures, including Vtesse and Tiburio Therapeutics.
Strategic collaboration announced between Enara Bio and Boehringer Ingelheim
12 January 2021
The partnership deal, worth over €876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
Theolytics raises $6.8M to advance oncolytic viral therapy against cancer
7 January 2021
Theolytics Series A funding round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI).
Enara Bio adds further world-class cell therapy and immuno-oncology expertise to senior leadership team and Scientific Advisory Board
16 December 2020
These appointments will provide experienced industry leadership and perspective to support Enara Bio's rapid growth and development in key strategic areas.
PepGen secures Series A funding
10 December 2020
RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases.
Enara Bio moves to The Oxford Science Park
9 December 2020
Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies.
UK BIA Antibody Taskforce reaches major milestone against COVID-19
10 November 2020
The UK Antibody Taskforce, led by Alchemab’s CSO, Dr Jane Osbourn OBE, has identified antibody combinations for a potential therapeutic antibody cocktail to treat COVID-19.
Base Genomics acquired by Exact Sciences for $410M
28 October 2020
The OSI backed venture and BioEscalator resident, Base Genomics has been acquired by the US based molecular diagnostics company, Exact Sciences for $410M.
Alchemab announced as finalists for OBN Awards 2020
5 October 2020
Novel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.
Alchemab collaborates with leading AI institute to advance drug discovery
30 September 2020
BioEscalator residents Alchemab Therapeutics has announced a partnership with the Alberta Machine Intelligence Institute (Amii), a global leader in machine intelligence.